Nurix Therapeutics Announces First Patient Enrolled in Phase 1b/2 Combination Study of Bexobrutideg in Chronic Lymphocytic Leukemia
Globe Newswire•07/10/2026•01:00 ET
1
Key Highlights
- ➤First patient enrolled in Phase 1b/2 bexobrutideg-venetoclax CLL combination study
- ➤Initial cohort targets relapsed/refractory CLL, with potential expansion to first-line patients
- ➤Study will evaluate combinations with Roche’s rituximab and obinutuzumab antibodies
- ➤Nurix and Roche plan broader bexobrutideg development across CLL and other B-cell malignancies
Expert Statements
Arthur T. Sands, Chief executive officer of Nurix Therapeutics
“The initiation of this study marks another important milestone in our effort to realize the full potential of bexobrutideg across B-cell malignancies.”
Arthur T. Sands, Chief executive officer of Nurix Therapeutics
“Combination therapies are becoming increasingly important in the treatment of CLL, especially in earlier lines of therapy, and we believe bexobrutideg’s differentiated mechanism of action, robust single-agent activity and favorable tolerability make it an attractive partner for combination approaches to deliver deep, durable responses with fixed-duration therapy.”
First patient enrolled in cohort combining bexobrutideg with venetoclax
Initial cohort to focus on relapsed/refractory CLL, with potential expansion to first-line CLL
Get started
Create a free account to read the full story.